Study aim: Evaluating the effect of topical combination galbanum oil and dry cupping therapy to alleviate COVID-19 patients symptoms Design: Clinical trial with control group with parallel groups, without blinding, randomized, phase 3 on 60 patients. Block randomization is used for randomization. Settings and conduct: Available standard treatment (according to the latest protocol of the Covid-19 headquarters) + Initially, 2 cc of galbanum oil is massaged in the back of the chest until the oil is absorbed into the skin + hot cupping behind the chest at a distance of 4 cm from the vertebral spines, fixed at point T4 for one minute and sliding on both sides of the spine to It is performed for 5 minutes, three times a day, at the time of hospitalization for 3- 5 days (from the first day of hospitalization to a maximum of 5 days of hospitalization). Hot cupping using a medium-sized balloon cup (cup opening width is 5 cm and cup height is 8 cm with a suction of about 10-15 mm). Place of study of Imam Khomeini Hospital Complex in Tehran Participants/Inclusion and exclusion criteria: Patients aged 18-80 years with positive PCR test COVID-19 With inpatient clinical criteria (T>38°C or severe cough or shortness of breath or RR> 24 per min or O2 sat <93%) non-entry: pregnancy Breastfeeding,coagulopathy disease, vertebral fracture or herniated disc Hearth and renal failure Intervention groups: The case group includes people who, in addition to standard treatment for coronavirus infectious disease, receive dry cupping and galbanum oil. The control group includes people who receive only standard treatment for coronavirus infectious disease. Main outcome variables: The primary outcome involves a recovery period in which the patient is in a position to: fever <37.2 ° in the early morning or <37.8 during the day - number of breaths ≤ 24 in room air - O2sat> 94 in room air and lack of cough or mild cough.